R&D channel feed

Bios­plice search­es for a path for­ward af­ter os­teoarthri­tis drug fails late-stage study

Last year

Ei­sai, BioArc­tic to de­vel­op new drug for Alzheimer’s that can cross blood-brain bar­ri­er

Last year
Deals

Boehringer In­gel­heim inks chron­ic liv­er dis­ease re­search pact with Ochre Bio

Last year
Deals

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Last year
In Focus

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Last year

Bris­tol My­ers pitch­es in to Pathios’ $25M Se­ries B for GPCR in­hibitor

Last year
Financing

Cerev­el notch­es Phase 3 Parkin­son's win ahead of Ab­b­Vie trans­ac­tion clos­ing

Last year

GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

Last year
Pharma

Sage nix­es pro­gram for Parkin­son’s dis­ease af­ter Phase 2 fail­ure

Last year

Sanofi's trimmed on­col­o­gy plans lead to $3B biobucks dent for IGM

Last year
Deals

Lil­ly plans for Zep­bound la­bel ex­pan­sion in­to sleep ap­nea in mid-2024 on back of Phase 3 win

Last year

GSK of­fers glimpse at pos­i­tive Phase 3 an­tibi­ot­ic da­ta for uro­gen­i­tal gon­or­rhea

Last year

Amy­lyx re­veals full da­ta that drove piv­otal fail­ure for ALS drug: #AAN24

Last year

In lat­est turn to au­toim­mune ther­a­pies, Cul­li­nan nabs $280M to join lu­pus space

Last year
Financing

In­tra-Cel­lu­lar on track for an­oth­er Caply­ta la­bel ex­pan­sion af­ter pos­i­tive Ph3 de­pres­sion da­ta

Last year

No­var­tis show­cas­es Ph3 da­ta for Fab­hal­ta in IgAN as FDA grants pri­or­i­ty re­view

Last year
Pharma

Ul­tragenyx preps for piv­otal tri­al in An­gel­man syn­drome, an area where oth­ers fell short: #AAN24

Last year

Mar­i­nus’ IV seizure drug faces ef­fi­ca­cy ques­tions as Ph3 con­tin­ues past in­ter­im analy­sis

Last year

Cash, chips and tal­ent: In­side Nvidi­a's plan to dom­i­nate biotech's AI rev­o­lu­tion

Last year
AI
In Focus

FDA hits Neumo­ra with clin­i­cal hold for schiz­o­phre­nia drug af­ter pre­clin­i­cal da­ta showed con­vul­sions in rab­bits

Last year

Roche’s Columvi pass­es Phase 3 lym­phoma test as com­pe­ti­tion with Ab­b­Vie, Gen­mab con­tin­ues

Last year

Adap­ti­m­mune los­es $3B biobucks pact with Genen­tech

Last year
Deals

En­livex’s shares cut in half af­ter ‘bi­as­es’ cloud Ph2 cell ther­a­py da­ta in sep­sis

Last year
Cell/Gene Tx

Fresh off ALS drug with­draw­al, Amy­lyx touts in­ter­im rare dis­ease da­ta for the same ther­a­py

Last year
First page Previous page 45464748495051 Next page Last page
A service from the Financial Times